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Abstract
BACKGROUND: Hypoglycemia can be a complication of diabetic ketoacidosis (DKA)
protocols. This prolongs time to DKA resolution, increasing hospital stay and mortality risk.
Does a revised DKA protocol reduce the incidence of hypoglycemia and reopening of the anion
gap due to inappropriate transition to subcutaneous insulin? There is a lack of published data in
the U.S. on factors affecting time to resolution of DKA and LOS in the ICU. This review was
focused on evaluation of safety outcomes and protocol effectiveness by comparing
hypoglycemia and hypokalemia events and instances of anion gap reopening for the duration of
DKA treatment.
PURPOSE: To evaluate the effectiveness and safety of a diabetes ketoacidosis (DKA) protocol
at UK Healthcare in patients with diabetes type 1: whether time to AG resolution, hypoglycemia,
hypokalemia and anion gap reopening incidences different following transition from old protocol
to a revised protocol.
METHODS: Retrospective chart review of patients managed with a DKA protocol before and
after protocol revision. Protocol efficacy was evaluated by assessing time to resolution of AG,
length of stay (LOS) in the hospital. Protocol safety evaluated by assessing the number of
incidences of hypoglycemic, hypokalemic events and events of anion gap reopening.
ANALYSIS: Comparison was done using descriptive statistics as well as parametric and
nonparametric tests to determine incidences of hypoglycemia, hypokalemia, anion gap that
reopened, time to anion gap resolution difference of 2 protocols. Comparisons of demographic
and clinical data of cohorts: t-test for continuous variables and the Mann-Whitney U tests.

RESULTS: 67 patients met biochemical inclusion criteria for DKA: median ages 32 and 31
years, 55% were males and 45% were females on average. The revised protocol (group 2, n=42)
did not show to be safer than old algorithm (group 1, n=28) in hypoglycemia events for duration
of the treatment with 44% (n=11) in the first group and 53% (n=22) for the second group. It did
not show to be safer in terms of hypokalemia, 40 % (n =10) of hypokalemia incidences in the
first group and 50% (n=21) in the second group (p=0.458). But it showed time in to anion gap
resolution was 3 hours faster when no hypoglycemia happened in the second cohort compared to
the first cohort and that the length of stay in ICU decreased by 1 day when no incidences of
anion gap reopening happened in the second group as compared to the first cohort. The protocol
showed to be safer for patients in terms of faster DKA resolution and shorter ICU LOS but not in
terms of incidences of adverse events. Individual factors associate with slower resolution of
DKA were lower admission pH (p=.029) in the first group but no correlation found in the second
group (p=0.735).
IMPLICATION/CONCLUSION: This project showed no difference in safety outcomes such as
hypoglycemia or hypokalemia but improved effectiveness outcomes such as faster AG resolution
between two groups. But it showed that increased safety (avoidance of hypoglycemia and AG
reopening) of the protocol leads increase in effectiveness and shorter ICU LOS in the second
group. Future studies should focus on the staff and providers compliance with following protocol
and timely transition from IV insulin infusion to SC insulin.
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BACKGROUND AND SIGNIFICANCE OF PROPOSED PROJECT
Problem Identification and Expected outcomes
Every year, more than 100,000 patients are admitted to U.S. hospitals for diabetic
ketoacidosis (DKA), and treatment costs exceed $1 billion (Bull et al., 2007). The mean cost of
hospitalization is about $7,500 per stay (Fayfman et al., 2017). DKA is a serious complication of
diabetes, which requires emergent interventions and treatments (Islam et al., 2018). DKA is a
metabolic disorder that includes hyperglycemia with ketoacidosis caused by excessive
production of ketones (Islam et.al., 2018). DKA protocols are designed to efficiently treat the
condition. Adverse events associated with the DKA treatment protocol can prolong the time it
takes to resolve the condition. Hypoglycemia and hypokalemia are the most common
complications of the treatment for DKA (Hirsch & Emmett, 2020). Protective strategies
recommended against treatment complications are low-dose intravenous insulin treatment and
thorough monitoring of potassium and blood glucose (Hirsch & Emmett, 2020).
Hypoglycemia can prolong time to DKA resolution and increase length of hospital stay
and mortality risk. Lorenson et al. (2019) investigated the incidence of hypoglycemia at 34 U.S.
hospitals, and determined that 35% of patients receiving standard DKA care developed the
condition. According to Dhatariya (2015), 28% of patients developed hypoglycemia after about
14.7 hours of treatment. Hypoglycemia has been associated with an 85% increase in the risk of
inpatient death, as well as a 2.5 day increase in LOS for each day of hypoglycemia (Turchin et
al, 2009). Suboptimal compliance with the DKA protocol with regard to inadequate monitoring
of K+ resulted in hypokalemia in a study by Kennedy et al. (2018). Two DKA protocols (old and
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revised) at a tertiary care center in Kentucky addressed hypoglycemia and hypokalemia
problems, and the objective of this project was to evaluate the differences in these outcomes.
The revised DKA protocol was a hospital-wide change for which implementation began
at the end of November 2018. As with the old protocol, the revised protocol addresses the
problem of hypoglycemia by: 1) the addition of 5% dextrose to fluid infusion when the threshold
for blood glucose (BG) is < 200mg/dL, and 2) insulin infusion rate reduction by half if BG falls
by >150mg/dL from the last BG concentration. This correlates with the American Diabetes
Association (ADA) guideline, which directs providers to change IVF with 5% dextrose 0.45%
NaCl at 150-250 ml/hr (Kitabchi, 2009). The revised protocol addresses hypoglycemia with 5%
dextrose fluids when BG is less than or equal to 250mg/dL, and a 50% reduction in insulin
infusion when BG is between 101-149 mg/dL. This simplifies the calculation step and places the
threshold for starting 5% dextrose at an earlier point. This also follows the Joint British Diabetes
Societies (JBDS) recommendation with the addition of glucose when blood sugar reaches 250
mg/dL. However, the JBDS recommends adding 10% glucose rather than 5%, and at a slower
rate of 125 ml/hr to run with 0.9% of NaCl plus KCl in order to avoid fluid overload and
hypokalemia. According to Lorensen et al. (2019), reducing the rate of insulin infusion when
initiating dextrose is protective against hypoglycemia. The 2009 ADA has indicated that a bolus
of insulin is not necessary if patients receive an hourly insulin infusion of 0.14 units/kg body
weight (equivalent to 10 units/h in a 70-kg patient), with a goal of reducing blood sugar by 50-75
mg from the previous value every hour after beginning treatment (Kitabchi, 2009). This
correlates with the revised protocol, which recommends the same insulin infusion rate but a
slightly higher threshold for the blood sugar goal: 50-100 mg/dL. According to 2009 ADA
guidelines, potassium replacement should be started when serum concentration is <5.2 to
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maintain a level of 4-5 mEq, as patients are total body depleted despite normal or elevated serum
results. Insulin infusion must be stopped when hypoglycemia or hypokalemia occurs (Kitabchi,
2009). According to Fayfman et al. (2017), this can cause rebound hyperglycemia, ketogenesis
and recurrent acidosis within about 10 minutes after abrupt cessation of insulin (half-life of
insulin is <10 min). Consequently, hypoglycemia or hypokalemia can both prolong DKA
resolution and increase risk of mortality due to cardiac arrhythmias and lack of BG to supply the
cells in the body. Potassium concentrations <3.3 can lead to life-threatening arrhythmias and
respiratory muscle weakness (Kitabchi, 2009). Also, during treatment, many patients with DKA
do not experience adrenergic manifestations of sweating, nervousness, fatigue, hunger, and
tachycardia—i.e., the signs and symptoms of hypoglycemia. This can lead to death; it is crucial
to check blood sugar every hour (Fayfman et al 2017). Hypoglycemic episodes can cause
seizures, arrhythmias and cardiovascular events. The aim of DKA protocols and guidelines is to
resolve DKA and reduce the incidence of hypoglycemia and hypokalemia. In this project, the PI
evaluated time to resolution of anion gap as a primary outcome and hypoglycemia (BG
<70mg/dL), hypokalemia (K+ <3.3 mmol/L) and anion gap (AG) reopening as safety outcomes
of a new DKA protocol at a tertiary care center in Kentucky.
The gap in the literature is that the recommendation for DKA management is often based
upon clinical judgment in the absence of scientific evidence. The gap in practice is the high rate of
dangerous hypoglycemic events and AG reopening, so a tertiary care center in KY revised its DKA
protocol to attempt to resolve these problems. This project included a thorough review of
published, databased literature about the most common adverse events associated with DKA
treatment protocols, such as hypoglycemia and hypokalemia. This body of literature included
numerous randomized controlled studies as well as the currently available ADA and JBDS
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recommendations on treatment modalities for DKA in order to facilitate faster resolution of the
problem. The PI compared studies, appraised evidence and uncovered data from a review of the
electronic medical record to determine incidences of hypoglycemia and hypokalemia at the tertiary
hospital in Kentucky and analyzed the findings to determine if the current protocol was more
effective at ensuring safe care for patients.
Context, Scope and Consequences
In a survey conducted in over 70 hospitals across the United Kingdom, adverse outcomes
such as hypoglycemia occurred in 27.6% of patients undergoing DKA treatment, and
hypokalemia in 55% of these patients (Dhatariya et al 2015). Because these adverse reactions are
so prevalent, it is important to follow recent, evidence-based guidelines when treating DKA.
Incidences of hypoglycemia and hypokalemia are higher when providers do not adhere to the
ADA and the JBDS recommendations (Gupta et al.2017, Munir et al.,2017; Thuzar et al.,2014
Dhatariya et al 2015). Also, following recommendations of the 2009 ADA guidelines yielded
better outcomes in hypoglycemia reduction than the JBDS recommendations (Lorenson et al,
2019). Researchers have shown that hospital and Intensive Care Unit (ICU) Length of Stay
(LOS) are longer when DKA treatment protocols do not follow clinical guidelines (Bull, et al.,
2007; Islam et al., 2018; Ramakkishnan et al., 2013). Additionally, the literature shows that the
time to DKA resolution is longer when non-protocolized treatment modalities or outdated
protocols are used (Fusco et al., 2015; Islam., 2018; Laliberte et al., Ramakrishnan et al., 2013;
Munik et al., 2017; Hara et al., 2013; Brown et al,2018).
Centers for Disease Control (CDC) reported age-adjusted DKA hospitalizations rates
steadily increasing from 2009 to 2014 at an average annual rate of 6.3% (Benoit et al., 2018).
Delays in DKA resolution and hypoglycemia put patients at a higher risk for prolonged
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hospitalization. Turchin at al. (2009) showed statistically significant increases in LOS and patient
death for every day of hypoglycemia. Longer term problems identified with poor blood sugar
control included kidney failure, cardiovascular problems, vision problems and stroke (McCary,
2018).
Evidence-Based Interventions
Despite available literature and multiple studies recommendation and the 2009 ADA
guideline consensus statement, it is not clear which protocol is best for DKA management,
because DKA protocols are based on clinical judgment rather than scientific evidence. DKA
protocol therapy is aimed at correcting hypovolemia, hyperglycemia, metabolic acidosis and
electrolyte imbalances (Bull et al., 2007). This project is important because of the lack of clear
studies in this area, and the numerous problems during DKA treatment such as high incidences
of adverse effects and a lack of consensus on standards of care among providers.
The revised protocol at this medical center was simplified, and the Primary Investigator
(PI) evaluated how efficient the protocol was to reach faster AG resolution and to avoid most
common complications, such as hypoglycemia and hypokalemia. The PI reviewed the hospital's
DKA protocol, compared it with recommendations from the literature, and highlighted the main
changes from the previous protocol. The new protocol has only two fluid options rather than
eight (isotonic 0.9% NaCl and 5% Dextrose 0.45% NaCl), which makes it more practical to use.
Also, it specifies K+ replacement before the start of the protocol, which correlates with the ADA
recommendation to replace K+ to reach at least 3.3 mmol/L before starting the insulin and a goal
to maintain K+ between 4-5 mmol/L. The change to the electrolyte replacement part of the
protocol (from premixed electrolytes and IV fluids to an electrolyte replacement sliding scale)
simplified the electrolyte replacement process and made it easier to keep K+ at goal. The old
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protocol required electrolytes to be premixed with IV fluids before treatment by the pharmacist
resulting in the need for constant IV fluid bags changes. The change eliminated possible
interruptions in treatment continuation caused by fluid bags not being readily available on the
ward. The multi-step insulin-dosing algorithm was modified to a two-step table with simplified
calculations on titration adjustments. The new protocol is easier to follow for the staff as its
instructions are clearer, simpler to follow and less time consuming, especially for the nurses who
are assigned higher acuity patients.
The first stage of the revised DKA protocol specifies titration adjustments when
BG >250 with the goal of a 50-100mg/hr BG decline and electrolyte replacement based on
biochemical profiles. The second stage: specifies IV fluids and insulin titrations if BG < or 250
with the goal of a 150-250 BG concentration. IV fluids are adjusted based on BG and serum
sodium concentration thresholds. Two types of IV fluids are isotonic 0.9% solution in the first
stage and 5% dextrose 0.45% NaCl in the second stage. When BG concentration reaches less
than 250 mg/dL then the IV fluids from the second stage are started. The ADA guidelines
recommended the fluid change after intravascular volume is restored and sodium (Na+)
concentration is normal (135mEq or >) or elevated, and addition of dextrose when BG reaches
200mg/dL with the goal that BG be >200 mg/dL. The revised protocol addressed Na+ correction
with 0.9% NaCL infusion (when corrected Na+ less than 135) or 0.45% NaCl (when corrected
Na+ more of equal to 135). Recent evidence showed that the outcome is not different when
continuous insulin infusion at rate of 0.14 units/kg/hr administered without bolus versus adding
bolus for faster blood sugar correction. Also, the literature recommends insulin infusion
continuation until ketoacidosis resolved, with serum BG < 200mg/dL and AG closure based on
the laboratory ranges of the individual facilities; and switch to subcutaneous (SC) insulin
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coverage after DKA resolution and 1-2 hours before infusion stopped (Hirsh & Emmet, 2018).
Current DKA protocol have only continuous insulin infusion without insulin bolus and have
references on when to switch to SC insulin and insulin drip discontinuation follows the most
available recent recommendation. The new protocol addresses the ADA’s goals for hypokalemia
and hypoglycemia prevention and uses the same fluid modalities and strategies for electrolyte
replacement, insulin infusion titration and monitoring as the ADA guideline.
Objectives/Purpose
The purpose of this project was to evaluate outcomes of currently used treatments for
hyperglycemic crisis in patients with type 1 diabetes and DKA.
Objective 1: First, to investigate the use of a new DKA protocol at tertiary care center in
KY in decreasing the number of hypoglycemic episodes.
Objective 2: Secondly, to investigate the number of episodes of hypokalemia that
occurred with the revised protocol and compare that to the number of episodes associated with
the old protocol.
Objective 3: Finally, to investigate whether the revised DKA could close the AG sooner
than the old protocol.
The revised protocol, designed for use with adult patients with DKA, came into effect on
November 28, 2018 at the tertiary hospital. The PI evaluated whether outcomes improved, and
hypokalemia and hypoglycemia episodes decreased six months after and six months prior to
implementation of the new protocol. Outcomes evaluated included the timeline to AG closure
timelines and blood sugar resolution (from time of insulin infusion start to first BG<250mg/dL,
and AG < or = 16 mEq/L).
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Theoretical Framework
The Framework for Continual Improvement of Health Care emphasizes continued
nursing education and by its application it is possible to define practice problems that can lead to
solving them (Batalden & Stoltz, 1995, see Appendix G).
In order to achieve medical advances and continue to improve practice, nurses must
combine knowledge with professional experience. For example, it is crucial to know anatomy
and microbiology, and to understand the nursing discipline and its values. Because of concerns
about the quality and efficacy of a protocol nurses must work with other health care disciplines
to make continual improvements.
Continual improvement involves a team approach. For instance, nurses working at their
best cannot meet their goal without the pharmacists working at their best as well. A single
department meeting their improvement goals is not enough; the whole healthcare team must be
involved in order to achieve lasting change. Leaders have to help workers understand the system
to facilitate this teamwork.
Variation or defect of event need to be understood in order to properly respond to the
problems. Is it common or special variation? Is AG resolution time increasing because of a
common variation, such as a faulty protocol that requires fundamental change in the process? Or
it is a special variation, such as provider’s non-adherence to the protocol or a late transition from
IV to SC insulin? By removing special causes or fixing common variations, improvements can
be made. Leaders must understand the psychology of change in order to help their followers
achieve it. Finally, the theory of knowledge involves the combination of an action with a theory.
If hypothesis about the cause of the problem or variation and attempted solution to the variation
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are close to actual response or desired outcomes, then the treatment is probably effective, and
this project evaluation is testing if the treatment of DKA is effective (Batalden & Stoltz, 1995).
Synthesis of the Evidence in the Literature
Diabetes ketoacidosis (DKA) is an acute complication of diabetes with increased
production and decreased clearance of serum ketones due to uncontrolled hyperglycemia.
Patients are severely dehydrated and develop metabolic acidosis. The PICOT question was: In
adults 18 years and older, how do evidence-based DKA treatment protocols based on recent
guidelines predict DKA resolution during a hospital stay, compared to DKA treatments that are
not based on guidelines?
The search started with a thorough review of the most recent articles about recommended
treatments for DKA, other conditions that can lead to metabolic acidosis and monitoring
standards to DKA resolution. The databases searched included PubMed, Ovid, National Medical
Library, CINAHL with Full Text, EMBASE, BMJ Clinical Evidence, Medline and UpToDate
system. Search terms included: DKA, hyperglycemic crisis, DKA protocol, diabetes
management, with narrowing to diabetic ketoacidosis, diabetic emergencies, hyperglycemic
emergencies searches to find information specific for insulin infusion treatments of DKA. The
search resulted in the selection of 15 articles from 2007 to 2019 and the ADA guidelines and the
JBDS. About 50% of the searched literature includes articles published between 2017 and 2018.
Eleven articles were evidence from guidelines developed from systematic reviews or evidence
from well-designed cohort studies, and the rest of the articles were quality improvement,
descriptive survey, and review designs. The search did not yield many randomized controlled
trials design studies to answer the PICOT question, so cohort studies were mostly the only
evidence to evaluate the practice.
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Evidence-Based Recommendations
The PI reviewed the literature focusing on treatment modalities and its outcomes, such as
a timeline for correction of ketoacidosis as well as safety indicators such as episodes of
hypoglycemia and hypokalemia.
According to the ADA, DKA diagnosis defined when BG > 250mg/dl, presence of
ketones in serums or urine and pH < 7.3 or bicarbonate < or= 18.0 mmol/L. The JBDS (2013)
recommends protocolized management of DKA, including fluid repletion with 0.9% NaCl as
initial IV fluids and aiming for ketone clearance with a weight-based fixed rate insulin IV drip
(Phillips & Sinha, 2018). The guideline states to infuse fluids within 24-36 hours and complete
half of those IV fluids within 8-12 hours of admission to correct dehydration (Islam et. al., 2018).
Bicarbonate administration is not recommended for metabolic acidosis correction unless pH <6.9
(Islam et al. 2018). Discontinuation of IV insulin should happen 2-4 hours after subcutaneous
(SC) insulin administration to avoid rebound hyperglycemia (Kitabchi, 2009). The ADA noted a
six-fold increase in the rate of hypoglycemia occurrence with the use of intensive insulin therapy
in medical ICU patients (n=1200) are not recommended except surgical ICU patient population
(Moghissi et al., 2009). Boluses of IV insulin, tight glycemic control and fixed rates are
considered intensive insulin therapies as referenced in the literature. When a patient is treated
with regular insulin, a starting threshold of glucose concentration should be ≤180 mg/dl. IV
insulin therapy should be kept at goal of 140 and 180 mg/dL from the time it is initiated and
targets <110 not recommended in critically ill patients in order to prevent hypoglycemia
(Moghissi et al., 2009).
The two-bag protocol is the addition of 10% dextrose IV fluids to a NaCl solution rather
than using one bag with only NaCl isotonic solution throughout the whole DKA treatment time.

14

This has been associated with faster hyperglycemia resolution and reduction in hospital and ICU
LOS by more than 20%. Using boluses in aiding faster hyperglycemia correction did not show any
differences in time for DKA resolution (Islam et al., 2018). In a randomized controlled study,
Brown et al. (2018) evaluated the effect of an insulin bolus compared to no bolus on the
management of DKA. They noted no difference in time to DKA resolution between the two
groups, no increase in incidences of hypoglycemia (no statistically significant findings) and no
difference in hospital LOS. Brown et al's study had a low sample size (n=145) and the potential
for inaccurate record keeping. One conclusion from this study is that it is safer to use the protocol
without insulin boluses because it has no benefit in faster resolution, but it can theoretically
increase the risk of hypoglycemic events.
Evidence-Based Protocol
In a randomized controlled study (RCS), Turchin et al. (2009; n=2582) found that
hypoglycemia occurs in an average of 8% of all admissions, and is strongly linked to increased
LOS and risk of mortality. The 2006 ADA guidelines recommended that the DKA drip include
an insulin bolus in addition to the fixed-rate insulin infusion, and this could have contributed to
an increase in hypoglycemia incidences. Hypoglycemia episodes were reduced when the insulin
infusion was titrated based on the 2009 ADA guidelines (Lorenson et al., 2019, Gupta et al.,
2016, Thuzar et al., 2014). Laliberte et al., (2017) noted no difference in hypoglycemia rates
with insulin infusion adjustments with bolus insulin administration as compared to insulin
titration without bolus. Conversely, a RCS by Thuzar et al. (2014) showed faster DKA
resolution, shorter LOS, and fewer hypoglycemic and hypokalemic events (p<0.05) by titration
of the IV insulin with a goal of BG between 160 to 250 mg/dl, addition of 10% dextrose
(100ml/hr) when BG reached 250 mg/dl or less, and replacement of K+ when serum K+ was less
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than 5. In their large RCS (n=256), Hara et al. (2013) noted a nine hour decrease in time to DKA
resolution with a similar treatment to the one used by Thuzar et al. (2014). However, they did not
find the difference in safety outcomes, such as reduction of hypoglycemia and hypokalemia,
compared to the treatment without protocol (p<0.05). Choosing the right IV fluids is important
for better efficacy and safety outcomes. In their RCS, Munir et al. (2017; n=383) evaluated
outcomes of one bag versus two bag protocols and noted clinically significant results, such as
faster AG closure and BG resolution and fewer hypoglycemia episodes with the two bag
protocol.
The protocol can be an effective tool to manage DKA and following the protocol closely
can improve outcomes, as the following studies show. Researchers have found that compared to
no protocol, DKA protocols yield faster DKA resolution (Bull et al., 2007; Ramakrishana et al.,
2013; Thuzar et al., 2014); reduce rebound DKA episodes (Ramakrishana et al., 2013), and
significantly reduce hypoglycemia and hypokalemia (Thuzar et al., 2014). A QI study (n=30) by
Kennedy (2018) showed that suboptimal compliance with the DKA protocol led to hypokalemia
(n=8). Ronsley et al. (2017; n=157) also noted low compliance in their study on a pediatric
population. Hence, better outcomes were related to protocol adherence.
Finally, in a large national study, Dhatariya et al. (2015; n=281) gathered data on DKA
management in 72 hospitals across the UK. They reported mixed findings, suggesting that the
fixed rate of insulin infusion could be too aggressive, resulting in increased hypoglycemia rates.
It was also confounding if high rates of hypokalemia and hypoglycemia were due to poor
adherence or faulty guidelines. The study evaluated DKA management with 70% of providers
following JBDS guidelines. The researchers noted 28% of patients receiving the DKA protocol
developed hypoglycemia with a median time of development at 15 hours after treatment started.
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They also found that 55% of patients receiving the DKA protocol developed hypokalemia
(Dhatariya et al., 2015).
In conclusion, the literature review revealed that DKA treatments based on the 2006
ADA guidelines cause high rates of hypoglycemia and hypokalemia, but researchers have noted
mixed results with the 2009 ADA guidelines as well. The rates of hypoglycemia and
hypokalemia are also prevalent with DKA treatment based on the JBDS guidelines. The review
revealed inconclusive results with regard to safety outcomes, and this could result from faulty
guidelines or poor adherence. Hence, there are no clear recommendations for providers.
However, resolution outcomes related to DKA seem to be better with slow insulin titration, and
with the right type of IV fluids (2 bag protocol over 1 bag protocol), based on biochemical
markers and electrolyte replacement to maintain BG and K+ at safe and steady levels. There is a
need to constantly evaluate outcomes and compare protocols to find the best possible evidence to
achieve better patient results. With these findings in mind, the PI chose to evaluate the variables
of time to AG resolution, AG reopening, hypokalemia, and hypoglycemia to better understand
the efficiency of the current protocol in use at the medical center in Kentucky.
Agency Description
Setting
The project focused on outcome evaluation of a DKA protocol at UK HealthCare in
Lexington Kentucky. The project focused on UK HealthCare Hospital, which is a 945-bed
medical center. It is a Level 1 Trauma center with approximately 40,000 patient visits to the ED
each year. The hospital serves Fayette and surrounding counties, with the largest population from
Eastern Kentucky (UK HealthCare). This organization is comprised of 9,000 healthcare
professionals, including physicians, nurses, pharmacists and other providers.
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The project involved the collection of data from all inpatient wards that treat patients with
DKA, including progressive units, ICUs and the ED. Registered nurses work closely with
advanced care providers, physicians and nursing care technicians to deliver critical care to DKA
patients. Critical care trained nurses can autonomously manage hyperglycemia crises with the
help of protocols. Care is provided continuously, 24 hours a day. Each unit can have its own
specific care guidelines in addition to the hospital-wide guidelines. Critical care units at UK
Chandler Hospital include cardiothoracic vascular intensive care unit, a clinical decision unit,
emergency and trauma services, medical intensive care units, progressive care units, and the
stroke center. There are 206 critical care beds at UK Healthcare that make up cardiothoracic,
medical, surgical, neurosciences and compose the setting for this project.
Target Population and Recruitment
UK Chandler Medical Center provides health care to all Kentucky counties. UK
HealthCare discharged 37,789 patients in 2016 (UK HealthCare, 2016). The target population for
this study was adults with type 1 diabetes who were admitted to the hospital with DKA as their
primary diagnosis and received DKA protocol treatment. The diagnosis of DKA is based on
ADA biomarker concentration obtained from venous blood gas and a serum chemistry panel
(Menchine, 2011). For safety outcome evaluation, the PI included a comparison of number of
episodes of hypoglycemia (blood sugar less than 70 mg/dL) and hypokalemia (potassium less
than 3.3 mEq/L; Kitabchi, et. al., 2008) and efficacy of the protocol was evaluated through
calculation of duration in hours for AG to reach 16 or less and calculation of duration of BG to
reach 250mg/dL. Other variables evaluated were admission pH <7.3 to determine relation to AG
closure.
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The PI collected laboratory values and demographic data through retrospective chart
reviews six months before November 28, 2018 (revised DKA protocol implementation day) and
six months after this day. According to data collected using the REDCap research informatics
tool, six months before November 28, the sample population included 25 subjects; six months
after implementation of the revised protocol, there were 42 subjects, for a total of 67 individuals.
The inclusion criteria were patients with diabetes mellitus type 1 (DM1). The exclusion
records of subjects included conditions such as DM2, uncompensated liver failure,
uncompensated kidney failure, myocardial infarction, fluid overload or severe impairment of a
vital organ during protocol examination days; pregnancy; and children under the age of 18 years.
Also, the PI excluded patients admitted to the hospital who used non-insulin treatments to treat
hyperglycemia and alcohol in their blood. The reason for exclusion was that all of the listed
problems could lead to erroneous interpretation of relevant laboratory results.
Alignment with Organizational Goals
The organization's mission corresponds with that of this project, specifically, to look for
cutting edge services on the level of the best providers in the nation, and lead the way to ensure
quality, safety and value for every patient. The protocol could be an effective way to resolve
DKA, or the project could produce new data so that any deficiencies can be improved. Also, the
project can lead to further studies to improve the protocol, encourage additional training, and to
encourage other researchers to work on improving knowledge about DKA treatment. The project
aligned with a strategic plan to reduce patients’ LOS and hence improve their experiences. So,
the actions to correct the problems can be developed with future studies that can result in a
reduction in a patient stay and bettering the quality of care and patient experiences. The strategic
plan addresses patient care by potentially limiting high-cost patient care expenses for treating the
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sickest. This means expansion of ambulatory patient care and a higher number of healthier
patients. DKA patients require emergent treatment and are included in the category of the sickest
patients. Additionally, UK HealthCare reported 810 patients on insulin for treatment of DKA and
non-DKA hyperglycemia who experienced hypoglycemia (blood sugar < 51) in 2018, and the
goal is to lower this number. If complications such as hypoglycemia can be avoided with an
efficient protocol, this can reduce the sickest patients’ expenses. This project served as
knowledge tool that indicated how well the DKA protocol aligns with the ADA guidelines and
the JBSG. This project was designed to support the academic role of the organization to advance
research and adopt evidence-based practices.
Stakeholders
There were multiple stakeholders or people who would be interested in protocol
evaluation. The primary stakeholders were nurses, nurses' techs and patients because they were
the targets of the efforts. Nurses implemented the DKA protocol and adjusted DKA treatments
based on MDs’ or other providers’ orders. NCTs were charting intake and output and checking
BG hourly. There were secondary stakeholders as well: medical doctors, advanced care
providers, nurse managers, and pharmacists who were directly responsible for reviewing orders
and adjusting orders based on biochemical results. Other key stakeholders included senior
clinical experts, Critical Care Services Councils, policy makers (those who sit on the committees
to approve the protocol), those who can influence others (CEOs) and those with academic or
research interests (Community ToolBox). These last groups of stakeholders were remotely
involved in the process of DKA implementation but were mostly working on safety
improvement and necessary changes to the DKA protocol at the population level.
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Facilitators and Barriers
Facilitators helped this evaluation project to be conducted efficiently. They involved
leadership support, IRB approval, and hospital mission alignment with the project goals and
outcomes. One of the main facilitating factors was the persistence of the evaluator and unfolding
results. But the biggest facilitator was that this protocol was already used hospital-wide; and it
was a change that need to be evaluated for effectiveness. The stakeholders who used the protocol
were interested to know if what they were implementing was actually working. Some barriers
included delays in data retrieval, staff shortage to retrieve the data, other research projects, and
technical problems.
Design
The PI used a retrospective cohort design for the chart review. This design was chosen
because chart evaluation involved comparison of sample groups available in records.
Retrospective chart reviews were used to see the outcomes of the protocol before it was revised,
for the time between 2018-05-28 and 2018-11-28 and after the change, for dates between 201811-28 and 2019-05-28.
Methods
Project Interventions
This project involved the collection of data from patient charts and included all inpatient
areas that treat patients with DKA, such as progressive care units, ICUs, and the ED. The study
includes only data extraction and interpretation without any intervention. Old and revised DKA
protocols were compared with the review of stored data, and outcomes of DKA treatments were
evaluated, such as episodes of hypoglycemia, hypokalemia, and the timeline for correction of
AG.
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IRB and Ethical Concerns
A letter of approval was received from the Nursing Research Council on June 12, 2019.
IRB approval was obtained on 10/2/2019 (#53236) in order to access the patients’ information.
After IRB approval, the PI reviewed patients’ extracted data done by CCTS with variables of
interest. CCTS practices and rules of compliance with HIPAA ensured the protection of
participants’ health information. It was not practical to obtain consent because the PI was doing a
fully retrospective EMR review. This project was granted exempt status because the PI used deidentified data of the patients’ records and the project was not defined as clinical research, so
consent was not required. The PI was not required to submit a waiver of authorization for
approval of data extraction, as data was de-identified by CCTS. The study did not include any
prospective data; therefore, there was no access to patients and no opportunity to seek informed
consent. The application was approved by IRB and a nonmedical type exemption was granted.
The risk to patients was minimal and did not pose any additional threat than the other
ethically reviewed studies. The only possible risk for the study was a breach of personal
information due to unforeseen breaches of privacy. The only people that had access to the data
were the University of Kentucky IRB, CCTS specialists, a statistician and the PI. This data for
this study will be kept for six years and the destruction of all research data will be done per UK
HealthCare policy. After IRB approval, the PI reviewed patients’ extracted data with variables of
interest.
The CCTS data extractor uploaded the data into REDCap. About two weeks after the
request was submitted the PI received an email that included a link to access the data. The data
were released to the PI in de-identified format. The PI did not make any attempt to identify the
subjects.
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The PI compared old and revised DKA protocols with the review of stored data,
evaluated outcomes of DKA treatments such as episodes of hypoglycemia, hypokalemia, and
timeline for correction of AG before change for the time between 2018-05-28 and 2018-11-28
and after change for dates between 2018-11-28 and 2019-05-28. Data collection included:
demographics (race, gender, age, ethnicity), length of ICU and non-ICU stay, lab values (venous
blood pH, K+, BG values, AG), LOS, admission disposition, discharge disposition.
Sample
The sample population included adult patients with diabetes type 1 as their primary
diagnosis for admission who received DKA protocol treatment at the Medical Center. The PI
chose convenience sampling because it was a review of all the patients' charts over a period of 6
months before and after the set date. The number of patients selected for chart review happened
to be at the hospital during the time period and were not randomly assigned. No other hospitals'
protocols were evaluated. The PI evaluated the difference between the "exposed" cohort (the
charts of patients treated with the revised protocol) and the "unexposed" cohort (the charts of
those treated with the old protocol). Two samples had an unequal number of participants.
The information collected included adults aged 18 and older, of both sexes, and the
sample population includes 25 and 42 patients in each group respectively. It excluded records of
subjects less than 18 years old, as well as cases with other conditions, such as uncompensated
liver failure, uncompensated kidney failure and evidence of alcohol intoxication because of the
possibility of data interpretation errors. Minors and pregnant women were excluded because of
variations in variables characteristics that can compromise laboratory results interpretation. The
sample evaluated was similar to the general population of patients with DKA, with the exclusion
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of conditions that can affect a proper evaluation of ketoacidosis resolution but no other
comorbidities.
Measures and Instruments. Implementation. Data Collection
The PI relied solely on objective data of biochemical tests that make my project valid.
Specifically, the PI examined patient outcomes by measuring a number of episodes of ↓BG (BG
<70 dL), ↓K (hypokalemia, K < 3.3) and timeline for AG closure (<16 mmol/L) and timeline to
BG resolution of 250 dL or less.
After data collection was completed by CCTS technicians, the PI reviewed the data and
further excluded cases based on DKA treatment noncompliance or misleading data when
laboratory values such as glucose were collected at longer than a 1-hour interval. This was
viewed as treating the patient with modalities other than the protocol, or as the use of a different
treatment to resolve DKA. Therefore, the excluded cases were identified and not counted in
statistical analysis. SPSS software was used to compare the data of two different protocols using
descriptive and inferential statistics and displayed the results of the findings with the help of
tables. After the findings interpretation, the results were shared with members of the project
committee.
Physical resources needed for chart review included a personal computer, since all patient
information was stored in electronic health records. The International Statistical Classification of
Disease and Related Health problems, 10th revision (ICD-10) was used to classify and code all
diagnoses for inclusion and exclusion criteria. Diagnosis search from 2019 ICD-10-CM included
code E10.10 (type 1 diabetes mellitus with ketoacidosis without coma). Admission type was
"emergency," because patients admitted to emergency are sent to other units when a bed
becomes available. So, the patients either stayed in the ED or transferred to subsequent units for
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treatment continuation. Exclusion criteria for the search included diagnosis coded as Z33, Z34,
Z3A (pregnant state) and K76.6 (decompensated alcoholic cirrhosis), R74.0 (lactic acidosis),
F10, (ingestion of drugs such as aspirin, methanol, ethylene glycol) and T45 (advanced chronic
kidney disease).
Data analysis
The PI compared the number of episodes of hypoglycemia, hypokalemia and an average
time to AG closure in both sample groups from the time of hospital admission until AG
resolution. This was based on biochemical results, and the PI used descriptive statistics (means
and standard deviations or frequency distributions) to summarize study variables. Using SPSS
software, the PI analyzed data and compared study variables with a two-sample t-test, chi-square
test of association or Mann-Whitney U test. All data analysis was conducted using SPSS, version
24 with an alpha level of .05.
Descriptive statistics were used to translate the characteristics of the sample into
measurable numerical data. AG resolution was counted as the serum AG reaching 16 or less
mmol/L. The PI compared number of patients, age, race, gender, glucose, adverse incidences of
low potassium and pH levels to evaluate differences in both groups at baseline and throughout
the timeframe of DKA treatment.
Results (demographics and findings)
Cohort 1 or group 1 included all patients who received treatment before the protocol
change and cohort 2 or group 2 included all patients who received treatment after the protocol
change occurred.
A higher proportion of patients were Caucasian compared to cohort 2 (92% vs. 74%,
p=.032). The majority of patients were in their early 30s (mean 32 vs. 31, p=.830). The
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progressive care unit was the most frequently admitted service with 48% for the patients in
cohort 1 and 52% in cohort 2 (p=.300). The average number of days spent in the hospital for
treatment of DKA with the old protocol was 5 days (p=.472), 3.5 with the new protocol, and 2
days in the ICU in both cohorts (p=.656).
In general, AG reopening was not associated with longer overall stay in the hospital
(p=.96). AG reopened in about 28% of patients in both cohorts and hypoglycemia episodes noted
for the overall duration of hospital stay were more than 96%, vs 93% in the first and second
groups respectively. Hypoglycemia that happened on the DKA drip before AG closure was
slightly higher in the 2nd group than in the 1st group, with 29% vs 24% (p=.683), so the revised
protocol did not result in fewer hypoglycemic episodes. But the rate of hypoglycemia on the
DKA drip for the duration of IV insulin infusion almost doubled in both groups (24%->44%->
and 29%->53%; p=.510). This may indicate that the patients were on the insulin drip after AG
closure, and this resulted in large increase in hypoglycemic episodes. Data suggest that the
transition to SC insulin was not timely.
Instances of hypokalemia were 40% in the 1st cohort and 50% in the second cohort
(p=.427). So, the revised protocol showed higher number of hypokalemic episodes, suggesting
that a sliding scale for K+ replacement could have resulted in more autonomy for the staff, but
also higher noncompliance either among providers or staff.
As compared to literature findings, hypoglycemia and hypokalemia rates were higher at
this medical center than what was found in the literature. For example, the rate of hypokalemia
was 28.6% (p=.038), and the rate of hypoglycemia was 8.6 % (p=.036) in the study by Thuzar et
al., (2014). Hara et al. (2013) had a 30.1% rate of hypokalemia (p=.413) and an 8% rate of
hypoglycemia (p=.259).
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Time to resolution of AG was 11.8 hours in the 1st group and 10.43 hours in the 2nd group
(p=.219), time to blood sugar resolution on average was 6.6 hours (1st group) vs 6.5 hours (2nd
group) in both cohorts (p=.883). Time to AG resolution was close to findings noted in the
literature. Patients treated with the 2009 ADA consensus statement protocol, had 13.6 hours for
DKA to resolve (n=113, p<.01) in Hara et al., study (2013) and 15 hours to DKA resolution
(n=35, p=.01), in Thuzar et al., study (2014).
For the adverse events and associated ICU LOS analysis, there was no significant
difference (p=0.643) when adverse events occurred (AG reopened) and when treatment had no
adverse events (as measured by ICU LOS) in the first group (n=25). For adverse event of AG
reopening in relation to ICU LOS, there was 3 ICU days on average when no event happened
and 4 ICU days when such event occurred. The AG reopening in this sample did not indicate
longer ICU stay (in days), compared to the cases when no AG reopening happened. For the
second group (n=42), there was a significant difference (p=.031) between incidences of AG
reopening and ICU length of stay (as measured by ICU LOS). In particular, the mean length of
ICU stays for patients whose AG reopened was 4 days compared to 2 days for patients who had
no instances of AG reopening. The AG reopening in this sample indicated longer ICU stay (in
days), on average, compared to the cases with no AG reopening. More patients required ICU
level of care in the second group 40.5 %, compared to the first group 30.8 % (p=.333)
Problem resolution analysis showed that in the first group of patients (n=25), the time to
AG resolution was not much different (11.5 vs 11.89 hours) when hypoglycemia episodes
occurred versus when there were no occurrences of hypoglycemia. There was no difference
between the timeline for AG resolution and hypoglycemia before AG closure (p=0.847) for the
first cohort. For the second cohort (n=42), the PI concluded that in those cases with no instances
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of hypoglycemia before AG resolution resulted in faster AG resolution, and this was statistically
significant (p=0.05). The majority of cases in the second cohort (n=30) had on average 9 hours to
AG resolution when there were no hypoglycemic episodes before AG closure. When
hypoglycemia did occur, the time to AG resolution increased by almost 4 hours, for a total of 13
hours.
Also, there was positive moderate association between incidences of pH less than 7.3 and
AG resolution for the first group, n=25 (Spearman’s rho .436, p=.029). But no association was
found between incidences of pH less than 7.3 and time to AG resolution in the second group,
n=42 (Spearman’s rho .055, p=.735)
Discussion
There was no significant difference in hypoglycemia episodes between cohorts.
Hypoglycemia episodes while on the protocol before AG closure were 24% for the first cohort
and 29% for the second cohort, with more patients in second cohort (p=.683). Interestingly,
patients had 96% and 92% of hypoglycemia episodes in the first and second groups throughout
the whole time spent in the hospital. This suggests that the protocol change did not result in a
smaller number of hypoglycemia episodes, and hypoglycemia rates were high for the duration of
the entire hospital stay. The study showed that hypoglycemia events between both groups were
not different for the first objective of the project.
The second objective was satisfied by calculating the number of hypokalemia episodes
that were higher in the 2nd cohort (40% vs 50%) but there was no statistically significant
difference between groups (p=.427).
Finally, for the third objective, AG resolution in hours was almost 2 hours faster in the
2nd group, (12 vs 10 hours; p=.22). AG closure was not related to hypoglycemia episodes within
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AG resolution in the second cohort (p=.847). It showed that the first cohort had 12 hours on
average for AG to close when no episodes of hypoglycemia occurred. However, there was faster
AG resolution in the second group when no hypoglycemia occurred during treatment before AG
closure (p=.05). Hypoglycemia incidences affected time to AG closure in the second cohort
(n=30), which was statistically significant. On average, it took 9 hours for the AG to close. Also,
in the second group, length of ICU stay was twice as long when AG reopened during the hospital
stay (p=.031). So, avoidance of hypoglycemia and AG reopening can help with faster problem
resolution and fewer days spent in the ICU.
Also, instances where venous pH was less than 7.3 were higher in the second cohort 64%
(n=16) and 75% (n=30; p=.343) were not statistically different between the two groups. But a
moderate positive association between low pH and time to treatment resolution was found. It
means an association between lower pH and longer time to treatment resolution (p=.029), when
no such association was found in the second group (p=.735). That can suggest that low pH was
attributed to other conditions rather than ketoacidosis, possibly affecting the laboratory values.
Limitations and Strength of the study
Small sample size was a significant limitation of this study. Sample size could increase if
the observation timeframe for both cohorts was broadened, but due to time constraints it was not
possible to achieve.
The number of people in both cohorts were not equal. There was a smaller sample size
than anticipated. Future studies could be done to evaluate compliance with the protocol
adherence among providers and staff as well as to evaluate comorbidities. Another study could
survey nurses about their attitudes about the protocol and provide feedback for improvement.
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The strength of the study is that there is no known DKA protocol treatment evaluation
study done at UK HealthCare.
Implications for practice, education, policy, and future research
Future studies should focus on hypoglycemia and AG reopening reduction as those
preventive strategies have been shown to promote faster AG resolution and shorter ICU LOS. The
next study can focus on a larger sample and employ a two-year timeframe for evaluation before
and after the revised protocol with inclusion of prospective study design; this should help to better
clarify the differences in protocols. The incidences of medication errors during drip infusion were
not evaluated in this study; future researchers could focus on that, since it can influence the
effectiveness of the treatment.
The protocol addressed hypoglycemia with low-dose insulin infusion without bolus and
addition of dextrose to IV fluids when blood sugar reached less than 250mg/dL. This follows the
2009 ADA guidelines, but there were no improvements in hypoglycemia cases between the two
groups. This raises questions about whether other factors may be affecting high rates of
hypoglycemia, such as staff nonadherence, and the need for accountability when following the
protocol. These factors should be evaluated in future studies. Also, the time from AG closure to
transition from DKA insulin drip to sliding scale can be evaluated because it can affect
hypoglycemia outcomes. Since, the results suggested long time to transition to SC insulin after
AG resolution occurred. A system alert is needed to notify the providers when AG closure occurs,
and it could be done by the pharmacists to reduce hypoglycemia with a timely transition to SC
insulin. These alerts can be a valuable tool and an important protective strategy since this
institution is a teaching hospital and many junior providers might not be aware of the specifics of
DKA management. Finally, future studies can focus on ways to reduce hypoglycemia, regardless
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of insulin drip infusion or sliding scale use. This number is very high throughout the hospital stay,
and on average occurs almost on every patient who is affected by diabetes.
Potassium replacement orders should be easily available for the nurses, with clear
instructions to start replacing potassium when values are between 4.1-5 or less than 4.1. There is
a need for a timely K+ replacements. It can be achieved by timely notifications or call back from
lab personnel to alert nursing. Also, pharmacists can verify orders for K+ replacement sooner.
Instructions about potassium K+ replacement and doses parameters should be included on the
algorithm in the same table next to IV fluids and IV insulin titration for better visualization.
Proactive, timely potassium replacement can help prevent hypokalemia, pauses in insulin drip
infusion and AG reopening.
Further research can evaluate the sustainability of the DKA protocol. In the next study,
researchers can examine costs and mortality numbers and compare those numbers after every 2
years of protocol implementation.
Summary/Conclusion
Outdated evidence-based DKA treatment modalities can lead to high numbers of adverse
outcomes. New evidence-based practices become available with time and there is a need to
implement that in the current practice.
This project was a retrospective review to assess the effectiveness and safety of the
currently used protocol in order to see what can be done to implement better protocols in the
future. There was no improvement in safety outcomes noted, such as less hypoglycemia or
hypokalemia, but the project did reveal better effectiveness outcomes, such as faster AG closure
timelines. However, the study noted that increased safety of the protocol can increase its
effectiveness and shorter ICU LOS. The study showed that AG resolution was on average 9
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hours when no hypoglycemia occurred, and it was about 4 hours faster than when hypoglycemia
occurred in the second sample group. Also, ICU LOS was two times shorter when incidences of
AG reopening did not happen in the second group. Biochemical results with lower pH were
related to longer AG resolution in the first group.
Since AG reopening was shown to significantly increase ICU LOS, strategies focused on
hypoglycemia rebound hyperglycemia, and hypokalemia should be explored since all of these
factors can cause AG reopening. Also, diabetic educators should be alerted when the lab values
are hitting or approaching critical values so as to actively participate in DKA management
teaching and helping staff and providers to understand the specifics of treatment. The review
revealed that labs to determine ketones in the blood serum were inconsistently ordered. The
majority of the providers ordered this laboratory on admission, and then very few ordered follow
up on ketone disappearance.
The study didn’t find that the revised protocol is less effective than the old algorithm.
Even though no improvements in safety outcomes were noted, there was faster DKA resolution,
which is consistent with other researchers’ findings on effects of the 2009 guidelines-based
protocols. Looking back at theoretical framework, the variation can be caused by special
circumstances, such as providers being unaware of the best time to transition to SC insulin, and
responding to this problem could reduce incidences of hypoglycemia. Also, nurses and
laboratory staff should work together to ensure more timely potassium monitoring, as well as
proactive and timely replacement.
Neither adherence to the protocol nor medical errors were evaluated in this project, and
should be evaluated in the next studies. Looking back at theoretical framework, the project
yielded valuable information and this information should be brought to the attention of the
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committee that is working on revision of the protocol so they can take these findings into
consideration. Strategies to avoid hypoglycemia and hypokalemia should combine knowledge of
DKA management as well as knowledge of the system, communicating and working with
providers, pharmacists, diabetic educators and nursing in order to explore possible solution for
improvement in safety outcomes. All three objectives were met as the number of hypoglycemic
and hypokalemic episodes was evaluated, as well as time to AG closure.
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Appendix A: Old DKA Algorithm
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Appendix B: Old DKA Algorithm ( IVFluids Titration)
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Appendix C: Revised DKA Protocol
Nursing guideline gNU-27 Adult DKA and HHS Guideline: ICU, ED and Progressive Use Only

Blood Glucose 251 mg/dL and higher

Insulin and Fluid Titration
Do NOT start insulin infusion if initial K ≤ 3.3 mEq/L, implement replacement per Electrolyte Replacement Protocol or notify provider for potassium orders AND
regarding delay in starting insulin infusion.

*Orders may
Initial DKA Insulin Infusion Rate: 0.14 unit/kg/hr (maximum: 14 units/hr) – Use DKA Insulin setting on Alaris® Pump
change based on
Stage
1
–
Begin
when
BG > 250 mg/dL (For BG 251 mg/dL and higher)
provider
Check BG every 1 hour. Follow titration table
discretion
STAGE 1
Insulin
IV Fluid + Electrolyte Management
If BG decreases > 101 mg/dL, within 1
hour (From last FSBS)
If BG decreases 50-100 mg/dL, within 1
hour (From last FSBS)
If there is any increase in BG or if BG
decreases < 49 mg/dL, within 1 hour
(From last FSBS)

Decrease current infusion rate by 50%
(Multiply current rate by 0.5)
Continue current infusion rate
Increase current infusion rate by 50%
(Multiply current rate by 1.5)

Fluid per physician order
For electrolyte replacement, use Electrolyte
Replacement Protocol if ordered. If not ordered contact
provider to get replacement orders as electrolyte values
result in SCM.

|

|

Check BG every 1 hour. Follow titration table
Stage 2 – Begin when BG < 250 mg/Dl (for BG 250 mg/dL and lower); Target glucose during stage 2 is 150-250 mg/Dl. Activate order for stage 2 insulin, Initiate
D5W-0.45% NaCl @ 100 ml/hr and discontinue all other IV fluids ordered with Stage 1 of DKA/HHS treatment. Continue electrolyte replacement described above.

Blood Glucose 250 mg/dL and lower

STAGE 2
If BG > 250 mg/dL, within 1 hour

If BG 150-250 mg/dL, within 1 hour

Insulin
Follow Stage 1 titration guidelines above.
Increase current infusion rate by 50%
(Multiply current rate by 1.5)
Continue current infusion rate

IV Fluid (Titrate hourly)
Restart previous IV fluids from Stage 1 at 250 ml/hr
D/C all D5W-containing IV fluids

If BG 101-149 mg/dL, within 1 hour

Decrease current infusion rate by 50%
(Multiply current rate by 0.5)

If BG 70-100 mg/dL, within 1 hour

Decrease current infusion rate by 50%
(Multiply current rate by 0.5, recheck BG in 30 minutes)

If BG <70 mg/dL

STOP insulin infusion. Give 25 g of dextrose 50% per
hypoglycemia management protocol, notify provider.

Continue or initiate D5W-0.45% NaCl at current rate
(Initial rate 100 ml/hr)
Increase D5W-0.45% NaCl by 50 ml/hr
May increase x3 to max rate of 250 ml/hr
Notify provider when 250 ml/hr is reached
Increase D5W-0.45% NaCl by 50 ml/hr
May increase x3 to max rate of 250 ml/hr
Notify provider when 250 ml/hr is reached
Adjust D5W-0.45% NaCl to infuse at 250 ml/hr and notify
provider

When BG > 100 mg/dL, restart insulin infusion at 50%
previous rate (multiply previous rate by 0.5).

When BG > 100 mg/dl, continue D5W-0.45% NaCl at 250
ml/hr.

Stage 3 - Transition to subQ insulin per provider order. Turn off insulin infusion 2 hours after first dose of subQ insulin. IVFs at the discretion of the provider.

40

Table 1: Synthesis of the Literature
Autho
r,
YEA
R
1.Bull
et al.,
2007

Sample
Characteristics &
Setting

Variables:
Independent
Dependent

Data Analysis

Main Findings

Design: RCS
Purpose: to
determine the
effect of a
mandatory
protocol for
treating
diabetic
ketoacidosis

Sample:
N= 241 (btw 20002005)
IG= 111(postprotocol)
CG=130 (preprotocol)
Jan 1, 2000- Dec 31,
2002 (preprotocol), and
Jun 1, 2003-Dec 31,
2004 (postprotocol),
with a principal DKA
diagnoses)
Setting:
University-affiliated
U.S. public teaching
hospital

IV= the
protocol
DV1= ICU
LOS
DV2= hospital
LOS
DV3=time to
correction of
AG and ketone
clearance
DV4=#hypogly
cemic episodes

Power analysis for this outcome performed
before beginning the study and use of a twosided test with an alpha of .05 and a power of
85%. Two groups compared using Student’s
t-test from SPSS version 12.0 (SPSS,
Chicago, IL) for Windows; p .05 was
considered to be significant.

Before protocol implementation, the mean SD ICU
and hospital LOS were 44 and 28 hrs and 91 and 73
hrs. After implementation, ICU and hospital LOS ↓
23% and 30%, to 34 and 18 hrs and 64 and 41
hrs, (both p < .007). Time to AG closure ↓ (both p
< .05. Number of hypoglycemic episodes- no
difference observed.

Design: RCS
Purpose:
to assess the
efficacy of a
unified
hyperglycemia
and DKA
insulin
infusion
protocol,
based on an
algorithm
aimed at
glycemic
targets and
minimizing
hypoglycemia

Sample: N=62
Surgical care
implementation project
n=20;
MICU n=42

IV: insulin
infusion
protocol
DV: blood
glucose
numbers

M data analyzed by t-tests or ANOVA. posthoc analysis was performed by the Fisher
LSD procedure for subgroup analysis.
Correlation and regression analysis was
performed using Pearson’s correlation
coefficient. Statistics on proportions were
performed by Chi square analysis.
Statistical procedures performed with
Statistica for Windows (Version 5, Statsoft
Inc., Tulsa OK). Significance was defined as
a P < 0.05 by two-tailed testing

BG targets of 100–180 mg/dL in majority patient
population. No episodes of hypoglycemia blood 4–
6 weeks. The two year pre-institution of the
protocol, # of hypoglycemic events ↓ (BG
<70MG/dL pre-protocol 2.87% vs post-protocol
2.30% < 0.001 ( statistically significant)

3.Fusc
o et al
2015

Design: RCS
for the
treatment of
DKA between
July 1, 2007
and June 30,
2010
Purpose:
determine if
treatment of
DKA in
MICU
patients was
consistent
with the 2006
ADA
Guidelines

Sample: N=60
(satisfying guidelines
n=12; not satisfying
guidelines n=48)
Setting:
University of Maryland
Medical Center MICU

IV: Diabetes
CG
DV1: IVF
DV2: insulin
gtt rate
DV2: transition
to SC insulin
DV3: # rebound
DKA, #
hypoglycemia

Descriptive statistics: demographic
information. Nominal data analyzed based on
the sample size using the chi-square test
and Fisher Exact test. Two-sample
student’s t-tests were used to evaluate
differences between 2 groups for continuous
discrete data. The Mann-Whitney U test evaluate differences between groups for
nonparametric discrete data. Statistical
analysis using StatPlus 2009 (AnalystSoft,
Alexandria,VA). A two-sided p-value of
<0.05 statistically significant

Low compliance with the 2006 ADA CG: Sixteen
(26.7%) patients were treated in compliance CG
with IVF infused. 10 (83.3%) out of 12 (by CG)
patients were appropriately transitioned to SC
insulin from insulin gtt vs 22 (45.8%) out of 48 (not
treated by CG) were transitioned to SC insulin from
an insulin gtt (p = 0.045). 5 (41.6%) of patients
treated by CG experienced an episode of rebound
DKA compared to 11 (22.6%) patients not treated
by CG (p = 0.342).

4.Isla
m et
al
2018

Design:
Review
Purpose: to
review

Sample: N=NA

IV=NA
DV-NA
MEDLINE (via
PubMed),

NA

treated with protocol -resolution of DKA in10 h.
After protocols-> ICU LOS ↓ 23% to 34+/18 h. M
hospital LOS ↓ 30% to 64+/41 h. Initial bolus
dose of insulin-> no significant benefit to DKA

2.Gup
ta et
al.,
2016

Study Design
Purpose

Settings: Saint Louis
University Hospital
(SLUH)

Setting: NA
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previous
guidelines,
choice of
therapy, cost,
need for
change to
existing
protocols to ↑
efficacy of
DKA
treatment, ↓
complications
and ↓
economic
burden of
DKA
5.Lali
berte
et al.,
2017

Autho
r,
YEA
R
6.Ken
nedy
et al
(2018)

7.Ron
sley et

EMBASE
searched (1 Jan
2000- 31 Dec
2017) by1
reviewer using
terms
“Management
of DKA”,
“Guidelines for
DKA”
“Cost/Burden
of DKA”.

Design: RCS
patients with
DKA admitted
to the MICU.
pre-order set
(PRE)
compared to
post-order set
(POST)
Purpose: To
determine
compliance to
the 2006 and
2009 ADA
DKA
guidelines

Sample: compliance
with 2006 guidelines
group: PRE n=12 (60
total); POST n=14 (55
total). Compliance with
2009 guidelines group:
PRE-order n=19 (60
total); POST-order n=36
(55 total)
Setting: MICU at a
large academic medical
center

Study Design

Sample
Characteristics &
Setting

Variables:
Independent
Dependent

Data Analysis

Main Findings

Sample N=30
patients admitted
btw Oct 2016-Oct
2017
Setting: Large
tertiary University
teaching hospital

IV: DKA protocol
DV1: knowledge and
attitudes
DV1: fluid
resuscitation
DV3: adequate
monitoring of
potassium

Descriptive statistics with univariate
analysis

Suboptimal compliance with DKA protocol with
respect to fluid resuscitation, adequate monitoring
of K+, with subsequent development of
hypokalemia in 8 patients

Sample N= 157
Setting: University
of British Columbia
Children's Hospital

IV: DKA protocol
DV1: initial lab
values

Log-linear regression analysis with
SAS/STAT Software version 9.4.

Health care providers' adherence to the DKA
protocol is poor, poor adherence to protocol’s
IVF. The length of time on insulin infusion was 21.5
and 24.1 hours in pediatrics

Purpose
Study design:
QI
Purpose: to
assess
knowledge and
confidence of
trainee doctors
in DKA
management
and adherence
to DKA
protocol
Study design:
RCS September
2008December 2013

IV1: PRE2006 CG
IV2: POST
2009 CG
DV1a: 24 h
volume in ml,
mean (PRE-)
DV2a: 24 h
IVF ml M
(POST)
DV1b:
hypoglycemia,
(%) (PRE)
DV2b:
hypoglycemia
(%) (POST)
DV1c: time to
DKA resolution
in h, M (IQR)
(PRE)
DV2c: time to
DKA resolution
in hours, M
(IQR) (POST)
DV1d: receipt
of insulin bolus
(PRE and
POST)
DV2d: insulin
gtt M (PRE&
POST)

patients. K excretion impaired in patients with renal
injury, K supplementation and insulin dose
adjustment needed in CKD patients. AG closure
earlier (10 h) with “two bag protocol” compared to
“one bag protocol” (14 h). Hyperglycemia
resolution faster in “two bag protocol” (7 h)
compared to “one bag protocol” (9 h)

Hypothesized ↑ compliance to 50%, 52
patients required, a power of 90% and a twosided a level of 0.05. Descriptive statistics demographic information and individual
outcome measures, IVF, insulin
administration and compliance rates.
Continuous variables - Student’s t-test or
Wilcoxon signed-rank test. The chi-square
or Mantel–Haenszel test was utilized for
categorical variables. To control for
confounding, a multivariate analysis
performed with a logistic regression model.
Statistical analyses performed utilizing
GraphPad Prism (GraphPad San Diego, CA,
USA).
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20% in the PRE group received treatment
compliant with the 2006 and 25.5% in the POST
group Compliance to the 2009 CG was
significantly ↑ in the POST group (31.7% vs
65.5%, OR 4.44 95% CI 1.8 to 10.92, P = 0.0004).
Time to DKA resolution ↓ (P = 0.04), and
hypoglycemia↑ (P = 0.0022). Only 20% of patients
received treatment compliant with the guidelines.
DKA treatment in the POST group was 4.44 times
more compliant to the 2009 ADA DKA guidelines
(contain the most updated recommendations in the
US for the care of patients with hyperglycemic
crises. Also, significantly ↑ compliance to 24-h IVF,
initial insulin gtt rate, time to DKA resolution and
appropriate transition to SC insulin in the POST
group. Limitations: small sample size,
confounding variables not assessed

al
2017

8.Turc
hin et
al
2009

Purpose: to
review
adherence to a
provincial DKA
protocol and the
length time on
an insulin
infusion
Study design:
RCS
Purpose: if
hypoglycemia
associated with
mortality in
diabetic
patients

DV2: insulin
infusion duration
DV3: lab values with
therapy

Sample: N=2582
Setting: 734-bed
teaching hospital

IV= # of days with
hypoglycemia
DV1= hospital
mortality
DV2= LOS

IV: 'Critical Care
DKA Protocol'
DV1: time to achieve
AG closure
DV2: # of
hypoglycemia
episodes
DV3: time to attain
blood glucose level
of 200 mg/dL
DV4: LOS in ICU
IV: one bag DKA
treatment
IV2: two bags DKA
treatment
DV1= AG closure
(resolution of DKA)
DV2= BG
<250mg/dL
DV3= time to reach
HCO3 > 18 mmol/L
DV4= LOS

9.Ram
akrish
nan et
al.,
2013

Study design:
RCS
Purpose: to
analyze the
impact of the
standardized
order set on the
management of
patients with
DKA

Sample : N= 165
(Oct 2005-Nov
2012):
before(n=80),
after (n=85), the
date of introduction
order set (Oct 2009)
Setting: MICU

10.Mu
nir et
al
2017

Study Design:
RCS from
2008-2015
Purpose:
compared the
conventional
‘one-bag
protocol’ of
management of
diabetic
ketoacidosis
(DKA) with the
‘two-bag
protocol’

Sample: N=383:
one-bag treatment
n= 249
two-bag n=134
Setting: Riverside
University Health
System Medical
Center

Author,
YEAR
11.Thuzar et
al., 2014

Study Design
Purpose
Study design:
RCS
Purpose: to
analyze whether
using a
standardized
protocol
improves clinical
outcomes in the
acute
management of
DKA

Sample
Characteristi
cs & Setting
Sample:
N=71 (Jan
2008-Mar
2012)
protocol group
n=35 (Jan
2010-Mar
2012)
control group
n=36 (Jan
2008-Dec
2009)

Variables:
Independent
Dependent
IV: DKA
protocol
DV: incidence of
hypoglycemia
(protocol vs
control)
DV2= incidence
of hypokalemia
(protocol vs
control)
DV3:M to
normalize serum

Frequencies, proportions, means, SD,
median ranges;
Summary stats for pt. demographics'
Wilcoxon test (# days and mortality,
LOS continuous variables); Fisher's
exact test for binary var.; logistic
regression for inpatient death
probability; SAS stat. software

Hypoglycemia was observed in 7.7% of
admissions. Hypoglycemia was associated with an
increase of 85.3% in the odds of inpatient death
(P = 0.009) and 65.8% (P = 0.0003) within 1 year
from discharge. LOS increased by 2.5 days for
each day with hypoglycemia (P < 0.0001)

Following outcomes were compared
between the two groups using unpaired
t test: 1. Time needed to achieve AG
closure, 2. Time needed to attain a BG
of 200 mg/dl, 3. LOS in ICU solely for
the purpose of management of DKA, 4. #
of hypoglycemic episodes. Not
statistically significant

The time to achieve AG closure (p = 0.036) and # of
hypoglycemic episodes (p = 0.014) significantly
lower in group 2. The time to attain BG level of 200
mg/dl and LOS in ICU were also lower in group 2
as compared to group 1, no stat. sig
The EHR-based ‘Critical Care DKA Protocol’ was
more effective than the conventional method of
insulin titration

Two-independent samples t-test for
continuous variables and χ2 test for
proportions for categorical variables
Outcome measures comparing the 1-bag
vs 2-bag protocols used to compare the
time to AG closure (primary outcome
measure) and time to reach BG
<250 mg/dL, time to reach HCO3 level
>18 mmol/L, and hospital LOS
(secondary outcome measures).
The relationship between the time to AG
closure and admission variables assessed
using Pearson product–moment
correlation. ANCOVA using AG closure
time as the DV, and admission variables
as covariates: patient’s age, weight, BMI,
admission pH and AG, BHB, BUN, Cr,
BG, HgbA1c, and the Charlson
Comorbidity Index. Data entered into a
Microsoft Excel spreadsheet and
analyzed using SAS V.9.3.

The AG closed in 13.56 hours in the 1-bag group vs
10.94 hours in the 2-bag group (p value <0.0002).
the 2-bag system favored earlier AG closure. BG
levels improved to <250 mg/dL earlier with 2-bag
protocol (9.14 vs 7.82 hours, p=0.0241). The
incidence of hypoglycemic events was significantly
less frequent with 2-bag protocol compared with
the standard 1-bag system (1.49% vs 8.43%,
p=0.0064).

Data Analysis

Main Findings

Data compared using two-tailed
Student's t -test, Chi-square and
Mann–Whitney U tests as applicable.
Quantitative data were expressed as
mean ± SD.
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the protocol group had significantly shorter
mean time taken to normalize serum
bicarbonate (15.1 h in protocol vs. 24.6 h in
control) ( P = 0.01), and mean length of
hospitalization (37.9 h vs. 49.2 h) ( P = 0.01).
The protocol group took 11.4 h less than the
control group ( P = 0.05). Incidence of
hypokalemia and hypoglycemia were
significantly lower in the protocol group; 28.6%
in the protocol group vs. 52.8% in the control
group for hypokalemia (P = 0.038), and 8.6% in

12.Hara et al.,
2013

13.Brown et
al., 2018

Study design:
RCS
Purpose evaluate
the efficacy and
safety of protocol
based upon the
2009 American
Diabetes
Association
(ADA)
consensus
statement
Study design:
RCS ( Sep 1,
2014-Jun 30,
2016)
Purpose: to
evaluate the
effect of an
insulin bolus, as
compared to no
bolus, on the
management of
DKA.

Setting: a
tertiary
Townsville
teaching
hospital in
Australia
Sample:
N=256:
nonprotocol n
=143;
protocol
n=113
Setting:
University
Medical
Center of
Southern
Nevada

bicarb (protocol
vs control)

the protocol group vs. 28% in the control group for
hypoglycemia ( P = 0.036).

IV= DKA
protocol
DV1= time to
resolution of
DKA or HHS
DV2= LOS in
the ICU
DV2=LOS in the
hospital

Protocol efficacy -time to resolution of
DKA or HHS, LOS in the ICU, and LOS
in the hospital. Protocol safety evaluated
for hypoglycemic and hypokalemic
events

Patients on the hyperglycemic crises protocol
experienced a 9.2 hour (95% confidence interval
(CI): 4.70-13.70; P<.001) decrease in time to
resolution, with nonprotocol patients ,no
difference in safety outcomes, including the
number of patients with moderate
hypoglycemia
Protocol decreased times to resolution of DKA
without increasing the rate of hypoglycemia or
hypokalemia

Sample:
N=145 Bolus
group n=58,
no bolus
group n=87
Setting:
Grady
Memorial
Hospital, 953
bed academic
medical center

IV: DKA
protocol
DV1: DKA
resolution
variables
(BG<200,
pH>7.3, AG
<12mEq,
Bicarb>15 mEq)
DV2: time to
resolution
variables,
Incidence of
hypoglycemia,
incidences of
hypokalemia

M , range: continuous variables.
Characteristics btw groups comparison:
Fisher's exact test for categorical
variable; non-parametric test: Wilcoxon
Rank Sum Test for continuous
variables. The Shapiro-Wilk test: to test
mortality; 0.05 sig. level;SAS 9.4

time to resolution of DKA from emergency
department admission did not differ
significantly between the insulin bolus and no
bolus group (15 vs. 15.9 h, respectively; p =
0.24). no difference in the secondary outcome,
time to resolution of DKA from insulin
infusion initiation between the insulin bolus,
and no bolus group (10.8 vs. 11.3 h,
respectively; p = 0.97). Receiving an insulin
bolus did not result in a higher incidence of
hypoglycemia (p = 0.64) or hypokalemia (p =
0.65) within 4 h of DKA protocol initiation. No
difference in length of hospital stay (p = 0.27)
or survival to hospital discharge (p = 0.40) was
observed
Limitations: non-randomized cohort design,
assignments by provider preference, confounding
variables not ruled out. Potential for inaccurate
record keeping, missing data, possibility of
resolution to occur prior to labs collected, not
ruled out

14.Dhatariya
(2015)

15. Lorenson et
al., (2019)

Design:
Descriptive
study/research
problem: survey
method
Purpose: to
conduct national
survey on DKA
management and
compare them
against national
standards with
JBDS guidelines

Sample:
N=281
Setting: 72
hospitals at
UK (May 1,
2014- Nov 30,
2014

Design: RCS
Purpose: to
evaluate
hypoglycemia
episodes
reduction in adult
DKA treatment
differ with fixed
insulin protocol

Sample=155
Cohort 1 n=77
Cohort 2 n=
78
Setting: in
423 bed
hospital, on 38
bed MICU

IV: JBDS
guidelines
DV: JBDS
compliance
(biochemistries
relevant to DKA
resolutions,
recommendation
adherence)

Descriptive statistics (mean, SD)
Surveys of providers (yes, no) with
questions to determine compliance
(biochemistries, DKA resolution) with
JBDS;
SPSS software

IV1: fixed rate
insulin infusion
DKA protocol
IV2: ratereduction when
initiating
dextrose protocol
DV:
hypoglycemia,
LOS, AG

Logistic regression -incidence of
hypoglycemia difference of 2 protocols);
Multiple regressionincidence of severe
hypoglycemia, administration of D50W,
rebound hyperglycemia) Continuous
outcomes : ordinary linear regression
(LOS in ICU, time to AG<or=12, time
until serum bicarbonate > or=15, serum
glucose prior to hypoglycemia, etc). ttest for continuous variables (age and

27.6% of patients developing overt
hypoglycemia at median time of 14.7 h after
treatment was started. possible that currently used
insulin drip regimen is too aggressive when BG
drop. Unclear if the development of low K and
BG levels is due to the poor adherence to the
CG vs CG are wrong.
Limitation: voluntary contribution of teams, no
direct review of medical records, inability to
verify accuracy of information.
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Hypoglycaemia was 19.2% in cohort 2 ver- sus
32.5% in cohort 1; use of dextrose 50% in water
(D50W) was also reduced in cohort 2. No
differences were seen in AG or bicarbonate
correction, rebound hyperglycaemia or ICU
length of stay.

vs empiric
insulin rate

resolution
timeframe

BMI) and Fisher's exact test for discrete
variables (gender, race and
comorbidities)
R statistical software 3.3

LEGEND: ↓ – Decrease; ↑ – Increase; ; CG – Control Group; CI – Confidence Interval; DV – Dependent Variable; IG – Intervention Group; PGplacebo Appendix
group IHMR –BIn-Hospital
Mortality
Rates; IV – Independent
Variable;
LOS – Length of Stay; M – Mean; RCS – Retrospective Cohort
Model for
Evidence-Based
Practice
Change
Study; RCT – Randomized Controlled Trial; SD – Standard Deviation; SPSS – Statistical Package for Social Sciences, ICU-intensive care unit,
AG-anion gap, DKA-Diabetic Ketoacidosis, IVF-intravenous fluids, BG- blood glucose, ADA-American Diabetes Association, CG- clinical
guideline, SC-subcutaneous, gtt-infusion/drip, K- potassium, Na-Sodium, CKD-chronic kidney disease, QI- quality improvement, BUN- blood urea
nitrogen, Cr- creatinine, JBDS- Joint British Diabetes Society

Table 2: Comparison of time to resolution and adverse outcomes between cohorts. Descriptive
statistics was used for each variable of interest
Variable
Time for AG to close (in
hours)
Time for glucose to
normalize (in hours)

n=25 Protocol # 1

n=42 Protocol # 2

p value

Mean (SD)
11.8 (4.23)

Mean (SD)
10.43 (4.46)

.22

6.6(2.31)

6.5 (2.88)

.883

Protocol #1 (before change), Protocol #2 (after change)
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Table 3: Comparison of demographic and clinical characteristics between cohorts
Cohort 1
Cohort 2
Variable
(n =25)
(n =42)
Age, Mean (SD)
32 (13)
31 (11)
.830
Gender, n (%)
Male
14(56%)
23 (55%)
.921
Female
11 (44%)
19 (46%)
Race, n (%)
Af. American
Other
Caucasian
Service, n (%)

2 (8%)
0 (0%)
23 (92%)

8 (19%)
3 (7%)
31 (74%)

.032

Pulmonary ICU
PCU
Other
Discharge disposition

8 (32%)
12(48%)
5(20%)

17 (41%)
22 (52%)
3 (7%)

.300

Home
Other

19(76%)
6 (24%)

35(83%)
7 (17%)

.434

5 (9.5)

3.5 (9)

.472

2(4.5)

2 (4)

.656

Hospital LOS,
median (IQR) in days
ICU LOS, median
(IQR) in days
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p

Table 4: Comparison of adverse outcomes between cohorts
Variable

Incidences of
AG reopening

Hypoglycemia
Yes
Hypokalemia
Yes
Hypoglycemia for
duration DKA drip
treatment before AG
closed
Hypoglycemia for
duration of DKA drip
treatment

Cohort 1
(n=25) n (%)

Cohort 2
(n=42) n (%)

7 (28%)

12 (29 %)

24 (96%)

39 (93%)

.599

10 (40%)

21 (50%)

.343

6(24%)

12 (29%)

.683

11 (44%)

22 (53%)

.510
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p

.960

Table 5: Comparison of treatment resolution within each group based on blood sugar
Independent sample T test

Time to AG resolution
(in hours) when
hypoglycemia
occurred within AG
resolution timeframe

Cohort 1 (n=25)
Mean (SD)
Yes (n=6)
No
11.50(3.39) (n=19)
11.89
(4.54)

P
.847

Cohort 2 (n=42)
Mean (SD)
Yes (n=12)
No (n=30)
13.17 (5.81) 9.33 (3.30)

P
.050

Table 6: Comparison ICU LOS and adverse event (AG reopening) within each group

ICU LOS (in days)
when AG reopened

Cohort 1 (n=25)
Mean (SD)
Yes
No
(n=7)
(n=18)
4.43
3.17
(2.07)
(6.91)

P
.643
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Cohort 2 (n=42)
Mean (SD)
Yes (n=12)
No (n=29)
4.25 (3.44)
1.69 (2.19)

P
.031

Figure 1: Framework for the Continual Improvement of Health Care, Batalden & Stoltz (1995)
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